Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.42 -0.38 (-0.98%) Market Cap: 5.61 Bil Enterprise Value: 4.90 Bil PE Ratio: 0 PB Ratio: 18.93 GF Score: 70/100

Ionis Pharmaceuticals Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript

Apr 01, 2022 / 05:00PM GMT
Release Date Price: $38.9 (+5.02%)
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology

All right. Good afternoon, and thank you for joining Guggenheim's Genomic Medicines and Rare Disease Conference day 2's last half of our session here. I am Debjit. I'm one of the analysts representing the Guggenheim Therapeutics team. It's my privilege to host Ionis Pharmaceuticals' Executive Vice President of Research, Dr. Eric Swayze.

Eric, thank you for your time today.

Eric E. Swayze
Ionis Pharmaceuticals, Inc. - EVP of Research

Well, thank you very much for having us on. Appreciate the opportunity.

Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology

Awesome. So let's just dial straight into it. Ionis' platform obviously has come a long way since mipomersen. You've been here for, you just said like, what, 24 years. You've experienced the whole highs and lows here.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot